Citius Pharmaceuticals Inc expected to post earnings of 33 cents a share - Earnings Preview

Citius Pharmaceuticals

09/05/2025 12:45

Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected to show a rise in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Cranford New Jersey-based  company is expected to report revenue of $2.668 million, according to the mean estimate from 2 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Citius Pharmaceuticals Inc is for earnings of 33 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $8.00‚Äč, above‚Äč its last closing price of $0.70. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.38
-0.58
-1.30
Missed
-125.4
Sep. 30 2024
-1.73
-1.50
-1.59
Missed
-6.1
Jun. 30 2024
-1.24
-1.25
-1.50
Missed
-20‚Äč
Mar. 31 2024
-1.50
-1.50
-1.25
Beat
16.7
‚Äč‚ÄčDec. 31 2023
3.25
3.25
-1.50
Missed
-146.2
Sep. 30 2023
-0.50
-2.00
Missed
-300‚Äč
Jun. 30 2023
-1.42
-1.37
-1.50
Missed
-9.1
Mar. 31 2023
-0.86
-0.87
-1.75
Missed
-100

This summary was machine generated May 9 at 11:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)